Expression profile of tyrosine kinases in breast cancer

被引:0
|
作者
Meric, F
Lee, WP
Sahin, A
Zhang, HX
Kung, HJ
Hung, MC
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[4] Univ Calif Davis, Ctr Canc, Dept Biol Chem, Sacramento, CA 95817 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tyrosine kinase (TK) family includes many growth factor receptors, cell cycle regulators, and oncoproteins. Moreover, the receptor TKs HER2/neu and epidermal growth factor receptor are overexpressed in a subgroup of breast tumors and correlate with more aggressive behavior. Thus, TKs are being actively pursued as therapeutic targets. The purpose of this study was to determine the expression pattern of TKs in breast cancer. Reverse transcription-PCR was performed with degenerate primers based on conserved motifs of the catalytic domains of TKs, and the identities of the reverse transcription-PCR products were determined by digestion with a panel of restriction enzymes. Using a TK display assay, we studied the TK profiles of 13 breast cancer cell lines and two normal immortalized breast epithelial cell lines. The TK display assay reproducibly demonstrated known differences in HER-2/neu expression between cell lines. Several TKs, including receptor TKs Axl, Cak, fibroblast growth factor receptor 4, HEK8, HER2/neu, c-MET, RET, and nonreceptor TKs ARG, BRK, Janus kinase 1, Rak, and YES were detected in breast cancer cells. Several kinases were differentially expressed among the cell lines. Similar TK profiles were found using RNA from human breast tumors. We conclude that there is significant variability in the TK expression pattern of breast cancers. This variability should be considered when selecting TK inhibitors to treat patients.
引用
收藏
页码:361 / 367
页数:7
相关论文
共 50 条
  • [31] Comparison of the expression profile in breast cancer and ovarian cancer
    Jarzab, M
    Dudaladava, V
    Simek, K
    BREAST CANCER RESEARCH, 2005, 7 : S47 - S47
  • [32] Comparison of the expression profile in breast cancer and ovarian cancer
    M Jarzab
    V Dudaladava
    K Simek
    Breast Cancer Research, 7
  • [33] ALTERED EXPRESSION OF SRC-RELATED TYROSINE KINASES IN HUMAN COLON CANCER
    ROSEN, N
    SARTOR, O
    FOSS, FM
    VEILLETTE, A
    BOLEN, JB
    MOLECULAR DIAGNOSTICS OF HUMAN CANCER, 1989, 7 : 161 - 166
  • [34] Analysis of expression of Eph/Ephrin tyrosine kinases in advanced ovarian cancer.
    Sabesan, SS
    Wyld, D
    Herath, N
    Boyd, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 480S - 480S
  • [35] Axl receptor tyrosine kinase expression in breast cancer
    D'Alfonso, Timothy M.
    Hannah, Jeffrey
    Chen, Zhengming
    Liu, Yifang
    Zhou, Pengbo
    Shin, Sandra J.
    JOURNAL OF CLINICAL PATHOLOGY, 2014, 67 (08) : 690 - 696
  • [36] Differential protein tyrosine phosphatase expression in breast cancer
    Rafferty, M
    McArdle, L
    Dervan, P
    Easty, D
    BRITISH JOURNAL OF CANCER, 2001, 85 : 45 - 45
  • [37] Tyrosine kinases as targets for cancer therapy
    Krause, DS
    Van Etten, RA
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02): : 172 - 187
  • [38] Significance of tyrosine kinases in cancer: overview
    Andersson, LC
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S2 - S2
  • [39] Tyrosine kinases as targets for cancer therapy
    Levitzki, A
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S11 - S18
  • [40] Nonreceptor tyrosine kinases in prostate cancer
    Chang, Yu-Ming
    Kung, Hsing-Jien
    Evans, Christopher P.
    NEOPLASIA, 2007, 9 (02): : 90 - 100